|
Cacciari, N., Zaagni, C., Martoni, A.: The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer, is it possible only with peripheral blood stem cell support?. Eur. J. Gynecol. Oncol. 21: 84-85, 2000. Cassinelli, G., Geroni, C., Botta, B., Delle Monache, G., Delle Monache, F.: Cytotoxic and antitumor activity of vismiones isolated from Vismieae. J. Nat. Prod. 49: 929-931, 1986. Cesano, A., Lane, S.R., Poulin, R., Ross, G., Fields, S.Z.: Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int. J. Oncol. 15: 1233-1238, 1999. Chabner, B.A., Levine, A.S., Johnson, B.L., Young, R.C.: Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat. Rep. 62: 429-433, 1978. Cheng, A., Peng, Z., Hong, Z.: A pharmacokinetic study of teniposide in intraperitoneal chemotherapy of ovarian cancer. J. West China Univ. Med. Sci. 30: 95-98, 1999. Cicchetti, S., Jemec, B., Gault, D.T.: Two case reports of vinorelbine extravasations: Management and review of the literature. Tumori 86: 289-292, 2000. Curtin, J., Barakat, R.R., Hoskins, W.J.: Ovarian disease in women with breast cancer. Obstet. Gynecol. 84: 449-452, 1994. Cushman, M., Mohan, P.: Synthesis and antitumor activity of structural analogues of the anticancer benzophenanthridine alkaloid fagaronine chloride. J. Med. Chem. 28: 10311036, 1985. Damia, G., Tagliabue, G., Zucchetti, M., Davoli, E., Sessa, C., Cavalli, F., D'Incalci, M.: Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother. Pharmacol. 30: 459-464, 1992. De Furia, M.D.: Paclitaxel Taxol ; : A new natural product with major anticancer activity. Phytomedicine 4: 273-282, 1997.
Exonuclease III ExoIII ; of Escherichia coli is a monomeric, globular protein 31 kDa ; combining different catalytic activities in one active site1. Its strong in vitro 3'-5' exonucleolytic activity on double-stranded ds ; DNA is extensively applied in molecular biological methods. A thermostabilized variant or a homologous thermophilic enzyme could expand the applicability of ExoIII for the in vitro recombination of DNA sequences2. The homologous enzyme from Archaeoglobus fulgidus has already been expressed and characterized in our group and was shown to posses a unspecific DNase activity under in vitro assay conditions3, limiting its possible application. Therefore further characterization of other thermophilic enzymes with homology to ExoIII was necessary to obtain information about substrate specificity and mechanisms of thermostabilization. In this study we show the expression and characterization of the MTH0212 gene product of Methanothermobacter thermautotrophicus, which is 50 % similar to ExoIII of E. coli. As DNA stability at elevated temperatures typical for thermophiles is influenced by DNA conformation and by salt concentration4, we paid special attention to the characterization of the enzymatic activity with different DNA substrates at various KCl concentrations.
Topotecan liposome
Data Elements and Data Values 240 250 26A Motor Vehicle Theft Counterfeiting Forgery False Pretenses Swindle Confidence Game Credit Card Automatic Teller Machine Fraud Impersonation Welfare Fraud Wire Fraud Embezzlement Stolen Property Offenses Receiving, etc. ; Destruction Damage Vandalism of Property Drug Narcotic Violations Drug Equipment Violations Betting Wagering Operating Promoting Assisting Gambling Gambling Equipment Violations Sports Tampering Bribery.
Table 2. Summary of Non-hematologic Adverse Events in Patients Receiving HYCAMTIN cont. ; Non-hematologic All Grades Grade 3 Grade 4 Adverse Event % Incidence % Incidence % Incidence n 879 n 4124 n 879 n 4124 n 879 n 4124 Patients Courses Patients Courses Patients Courses Body as a Whole Fatigue 29 22 5 Fever 28 11 1 Pain * 23 11 2 Asthenia 25 13 4 Skin Appendages Alopecia 49 54 NA Rash 16 6 1 Respiratory System Dyspnea 22 11 5 Coughing 15 7 1 CNS Peripheral Nervous System Headache 18 7 1 Pain includes body pain, back pain, and skeletal pain. Rash also includes pruritus, rash erythematous, urticaria, dermatitis, bullous eruption, and maculopapular rash. Premedications were not routinely used in these clinical studies. Hematologic: See WARNINGS. ; Gastrointestinal: Nausea incidence 64% 8% grade 3 4 vomiting 45% 6% grade 3 4 ; of patients see Table 2 ; . The prophylactic use of antiemetics was not routine in patients treated with HYCAMTIN. Diarrhea 32% 4% grade 3 4 ; , constipation 29% 2% grade 3 4 ; , and abdominal pain 22% 4% grade 3 4 ; . Grade 3 4 abdominal pain was 6% in ovarian cancer patients and 2% in small cell lung cancer patients. Skin Appendages: Total alopecia grade 2 ; 31%. Central and Peripheral Nervous System: Headache 18% ; , paresthesia 7% of patients, generally grade 1 ; . Liver Biliary: Grade 1 transient elevations in hepatic enzymes 8% ; . Greater elevations, grade 3 4 grade 3 4 elevated bilirubin 2% ; . Respiratory: Grade 3 4 dyspnea was 4% in ovarian cancer patients and 12% in small cell lung cancer patients. Table 3 shows the grade 3 4 hematologic and major non-hematologic adverse events in the topotecan paclitaxel comparator trial.
Vein was the common denominator, the authors studied renal patterns in dogs with experimental renal vein occlusion. The clinical syndrome of renal vein thrombosis occurs most frequently over 50 per cent ; in children, with ileocolitis being the chief predisposing cause. In adults the condition may be secondary to thrombosis of the inferior vena cava with extension into the renal vein. Very seldom, according to the literature, has a definite diagnosis been made ante mortem in these cases. The authors present the findings in 3 patients with renal vein thrombosis and point out that the diagnosis may be suspected roentgenologically by the demonstration of an enlarged kidney, which on pyelography presents a "pseudoeystic" appearance.
The value of Ci will also affect turn-on pops Refer to Effective Bypass Capacitance ; . The bypass voltage ramp up should be slower than input bias voltage. Although the bypass pin current source cannot be modified, the size of CBYPASS can be changed to alter the device turn-on time and the amount of clicks and pops. By increasing the value of CBYPASS, turn-on pop can be reduced. However, the tradeoff for using a larger bypass capacitor is to increase the turn-on time for this device. There is a linear relationship between the size of CBYPASS and the turn-on time. In a SE configuration, the output coupling capacitor, CC, is of particular concern. This capacitor discharges through the internal 10K resistors. Depending on the size of CC, the time constant can be relatively large. To reduce transients in SE mode, an external 1K resistor can be placed in parallel with the internal 10K resistor. The tradeoff for using this resistor is an increase in quiescent current. In the most cases, choosing a small value of Ci in the range of 0.33F to 1F, Cb being equal to 4.7F and an external 1K resistor should be placed in parallel with the internal 10K resistor should produce a virtually clickless and popless turn-on. A high gain amplifier intensifies the problem as the small delta in voltage is multiplied by the gain, so it is advantageous to use low-gain configurations. Shutdown Function In order to reduce power consumption while not in use, the APA2069 contains a shutdown pin to externally turn off the amplifier bias circuitry. This shutdown feature turns the amplifier off when a logic low is placed on the SHUTDOWN pin. The trigger point between a logic high and logic low level is typically 2.0V. It is best to switch between ground and the supply VDD to provide maximum device performance. By switching the SHUTDOWN pin to low, the amplifier enters a low-current state, IDD 1A. APA2069 is in shutdown mode. On normal operating, SHUTDOWN pin pull to high level to keep the IC out of the shutdown mode. The SHUTDOWN pin should be tied to a definite voltage to avoid unwanted state changes and toradol.
Topotecan chemotherapy drugs
Dark 1: 200, anti-mouse-FITC-conjugated, Sigma Aldrich, St. Louis MO ; . Chambers were removed and ~60 L DAPI fixation solution was spotted on the slide. Cover slips were secured with nail polish and the slide was left to dry in the dark for ~15 min then examined using a fluorescence microscope.
Time of it as some people thinks they have. I've often wondered as they take so much trouble, and works away so patient trying to find out the rights and wrongs of things for people that they never saw before, and won't see again. However, they try to do their best, all as I've ever seen, and they generally get somewhere near the right and justice of things. So the judge began and read -- went over the evidence bit by bit, and laid it all out before the jury, so as they couldn't but see it where it told against us, and, again, where it was a bit in our favour. As for the main body of the cattle, he made out that there was strong grounds for thinking as we'd taken and sold them at Adelaide, and had the money too. The making of a stockyard at the back of Momberah was not the thing honest men would do. But neither of us prisoners had been seen there. There was no identification of the actual cattle, branded `HOD', alleged to have been stolen, nor could Mr. Hood swear positively that they were his cattle, had never been sold, and were a portion of his herd. It was in the nature of these cases that identification of live stock, roaming over the immense and toremifene.
Other agents currently under investigation include diazoquinone , dacarbazine , acnu , trimetrexate , melphalan , mcnu , topotecan , busulfan , mafosfamide , lymphokine-activated killer cells and il-2 , au-colloid , and gene therapy.
Table 3. Symptom improvement compared with baseline in patients with SCLC treated with i.v. topotecan or CAV Symptom Anorexia Chest pain Cough Dyspnea Fatigue Hemoptysis Hoarseness Insomnia Interference with daily activities and torsemide.
Dition to EGFR, Topo I regulates other, as-yet-unidentified genes that are involved in the positive regulation of proliferation. Importantly, all of the data presented here concerning the role of c-Jun and Topo I on EGFR gene expression have been obtained by interfering with endogenous Topo I and c-Jun and by studying expression of genes in their proper chromatin context. Earlier in vitro studies have shown that Topo I is involved in transcription only if it is recruited to the promoter by a transcription factor 28, 34 ; . Our findings with c-Jun cells show that Topo I supports EGFR transcription only in c-Jun positive cells Fig. 4A and B ; , providing the first in vivo evidence that an interacting transcription factor is required for Topo I function on gene regulation. Moreover, our results show that constitutive JNK2 activity in HT-1080 cells stimulates c-JunTopo I interaction and is required for topotecanelicited inhibition of EGFR expression Fig. 2D and 4C ; . The specific requirement for constitutive JNKc-Jun pathway activity for cooperation of c-Jun and Topo I on EGFR gene regulation may explain why EGFR has not been identified as a target gene for topotecan in other studies 5 ; . On the other hand, our results show that many genes regulated by c-Jun are not inhibited by topotecan, suggesting that the role of Topo I on gene regulation is not solely determined by its interaction with c-Jun. This may be explained by requirement of other, as-yet-unidentified regulatory proteins that are selectively involved in c-Jun-mediated regulation of the EGFR promoter. In addition to its functions on chromatin 28 ; , Topo I exerts its effects on transcription through assembly of the TFIID-TFIIA complex 17, 26, 34 ; . Interestingly, TFIID was shown to predominantly deliver TBP to TATA-less promoters, whereas SAGA predominantly delivered TBP to TATA-containing promoters 1 ; . EGFR gene promoter is TATA-less 13 ; . Both c-Jun and Topo I has been demonstrated to bind to TBP in vitro 10, 17, 26 ; , and in the present study we provide evidence for a physical in vivo interaction between TBP, Topo I, and c-Jun Fig. 2A ; . Based on these considerations, it is tempting to speculate that EGFR might serve as a prototypical example of a gene whose TATA-less promoter requires Topo I activity for TFIID complex assembly and for TBP binding. In the future, it would be of great interest to determine whether the specificity of Topo I in gene regulation is determined by the promoter structure and or by other, as-yet-unidentified proteins. Increased JNKc-Jun pathway activity has been detected in various malignancies 24 ; . The results of our study are in accordance with recent studies indicating that the molecular mechanism by which JNKc-Jun signaling promotes cancer cell growth involves transcriptional stimulation of EGFR expression 3, 7, 13, ; . Our results show that constant JNK activity in HT-1080 cells is required for c-JunTopo I interaction and for the EGFR-dependent proliferation of these cells. Importantly, the results of the present study indicate that the activity of JNKc-Jun signaling pathway determines the sensitivity of cancer cells to Topo I-inhibiting chemotherapy. In addition to elucidating the mechanisms by which the sensitivity of cancer cells to topotecan is regulated, these results may provide important information for the future development of cancer therapies aimed at inhibition of JNKc-Jun pathway activity 24 ; . In the future it would be of great interest to study whether the.
Topotecan hycamtin treatment
Platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 2000; 78: 228-234. Homesley HD, Hall DJ, Martin DA et al. Weekly bolus topotecan toxicity and dose response trial in second or third line therapy of epithelial ovarian carcinoma. Proc Soc Clin Oncol 2000; 19: 395a. Frasci G, Nicolella G, Comella P et al. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony and tracleer.
Which results in high topotecan ventricular CSF penetration. Besides Bcrp1, we also detected P-gp expression in mouse choroid plexus. Unlike Bcrp1, the immunohistochemical staining pattern of P-gp in choroid plexus seemed to be more uniformly scattered and granular throughout the cytoplasm versus being discretely localized to the border of epithelial cells. The granular pattern noted in our samples has previously been observed in the choroid plexus of rat, nonhuman primates, and human 37, 38 ; . It is commonly recognized that P-gp has a predominantly subapical distribution in choroid plexus epithelia 37, 39 ; . In this case, P-gp may also play a role in transporting topotecan into the CSF. In conclusion, topotecan brain ECF penetration was much lower compared with ventricular CSF penetration. Gefitinib increased topotecan brain ECF penetration but decreased ventricular CSF penetration. These results are consistent with the possibility that expression of Bcrp1 and P-gp at the apical side of the choroid plexus facilitates an influx transport mechanism across the bloodcerebrospinal fluid barrier, resulting in high topotecan CSF penetration, which could be inhibited by tyrosine kinase inhibitors like gefitinib. To determine if this is clinically relevant, it will be necessary to examine whether BCRP is also expressed at the apical side of the human choroid plexus. Our results also suggest the possible use of tyrosine kinase inhibitors to enhance brain parenchymal ECF penetration of selected anticancer drugs in the clinic. However, caution must be taken in combining tyrosine kinase inhibitors with anticancer drugs because this may not necessarily enhance the CSF drug penetration for drugs that are substrates for influx transporters.
Platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 1062-1067. Kaufmann SH, Peereboom D, Buckwalter CA et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88: 734-741. Chou TC, Motzer RJ, Tong Y et al. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524. Rowinsky EK, Grochow LB, Hendricks CB et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-656. Wall JG, Burris 3rd HA, Von Hoff DD et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan SK&F 104864 ; given as an intravenous bolus every 21 days. Anticancer Drugs 1992; 3: 337-345. Clarke-Pearson DL, Van Le L, Iveson T et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001; 19: 3967-3975. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-2193. Gore M, ten Bokkel Huinink W, Carmichael J et al. Clinical evidence for topotecan-paclitaxel noncross-resistance in ovarian cancer. J Clin Oncol 2001; 19: 1893-1900. Rowinsky EK, Kaufmann SH, Baker SD et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996; 14: 3074-3084. Speyer J, Hochster H, Wadler S et al. Effective first line therapy of ovarian cancer OC ; with cisplatin and prolonged topotecan infusion--A NYGOG ECOG Study. Proc Soc Clin Oncol 2000; 19: 380a. Estape RE, Angioli R, Mendez L et al. 3-day topotecan and carboplatin in first line treatment of ovarian cancer: a phase II trial. Proc Soc Clin Oncol 2001; 20: 219a. Hochster H, Wadler S, Runowicz C et al Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 1999; 17: 2553-2561. Frasci G, Panza N, Comella P et al. Cisplatin-topotecanpaclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann Oncol 1999; 10: 355-358. Armstrong DK, O'Reilly S, Bookman M et al. A phase I study of topotecan T ; , cisplatin C ; and paclitaxel P ; in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group GOG 9602 ; study. Proc Soc Clin Oncol 1998; 17: 350a. Herben VMM, Panday VRN, Richel DJ et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J Clin Oncol 1999; 17: 747-755. Downloaded from TheOncologist by on March 26, 2008 and trandolapril.
Topotecan and cervical cancer
In this study, estrogen antagonists and agonists increased the cellular accumulation of topotecan in BCRP-expressing cells and reversed BCRP-mediated drug resistance. Estrone and diethylstilbestrol enhanced the cytotoxicity of SN-38 and mitoxantrone on K562 BCRP cells, whereas they did not affect the cytotoxicity of either of these drugs on K562 cells. Diethylstilbestrol showed stronger BCRP-reversing activity than estrone. Estrone at 3 M and diethylstilbestrol at 0.5 M showed similar reversing effects of SN-38 and mitoxantrone resistance in K562 BCRP cells. Therefore, diethylstilbestrol may be a practical parental compound for the screening of BCRP antagonists. However, diethylstilbestrol showed a strong growth inhibitory effect even at 1 M. Diethylstilbestrol dipropionate showed weaker BCRP antagonist activity and growth inhibitory effect than diethylstilbestrol. We chose a chemical library of tamoxifen derivatives to screen for BCRP antagonists. This rationale was based on.
Fig. 1. Exposure of retinoblastoma cells to topotecan, vincristine, carboplatin, and etoposide in culture. A, Y79 and Weri1 retinoblastoma cell growth properties in RPMI were monitored to determine their optimum growth density. B, cell number, cell viability [calcein ethidium bromide EthBr ; ], and apoptosis TUNEL ; was used to calculate see Materials and Methods ; the viable cell number at each time point. The proportion of BrdU BrdU ; labeled cells representative of the percentage of proliferating cells was determined separately red bars ; . Bars, 10 Am. C, Y79 cells were exposed to different concentrations of topotecan TPT ; , vincristine VCR ; , or carboplatin CBP ; for 8 hours. Seventy-two hours later, the cell number and proportion of metabolically active cells calcein ethidium bromide ; , apoptotic cells TUNEL ; , and dividing cells BrdUrd ; were scored and plotted. The concentration required to reduce cell viability by 50% LC50 ; is indicated by a dashed line. D, vincristine 0.005 Amol L; VCR ; and carboplatin 4 Amol L ; were combined with a broad range of etoposide ETO ; concentrations dashed line ; , and viability was determined forY79 shown ; and Weri1cells. For comparison, a parallel experiment was carried out with etoposide alone solid line ; . Topotecan 0.03 Amol L ; was combined with different concentrations of carboplatin or vincristine concentrations dashed line ; , and viability was determined. For comparison, a parallel experiment was carried out with carboplatin or vincristine treatment alone solid line ; . Points represent duplicate experiments done in triplicate and tranylcypromine
Differential HLA Gene Expression in Responders and NonResponders to Measles Vaccine Virus MVV ; using GeneChip Expression Arrays N. Dhiman, R. B. Guerrero, R. M. Jacobson, D. J. O'Kane, G. A. Poland Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, MN and topotecan.
Topotecan ewing
11. Gupta, E., and Ratain, M. J. Camptothecin analogues: topotecan and irinotecan. In: Grochow, L. B., and Ames, M. M. eds. ; , A Clinician's Guide to Chemotherapy. Pharmacokinetics and Pharmacodynamics, pp. 435 457. Baltimore: Williams & Wilkins, 1998. 12. Gerrits, C. J., Burris, H., Schellens, J. H., Planting, A. S., van den Burg, M. E., Rodriguez, G. I., van Beurden, V., Loos, W. J., Hudson, I., Fields, S., Verweij, J., and von Hoff, D. D. Five days of oral topotecan Hycamtin ; , a phase I and pharmacological study in adult patients with solid tumours. Eur. J. Cancer, 34: 1030 1035, Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31 41, Rosing, H., Doyle, E., Davies, B. E., and Beijnen, J. H. Highperformance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J. Chromatogr. B Biomed. Appl., 668: 107115, 1995. Zamboni, W. C., Houghton, P. J., Johnson, R. K., Hulstein, J. L., Crom, W. R., Cheshire, P. J., Hanna, S. K., Richmond, L. B., Luo, X., and Stewart, C. F. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J. Pharmacol. Exp. Ther., 284: 89 94 and treprostinil.
PS5.27 COMPREHENSION AND PRODUCTION OF LINGUISTIC AND AFFECTIVE PROSODY IN CHILDREN WITH AUTISM Danielle E Delosh, Ruth B Grossman, Rhyannon H Bemis, Christine Connolly, Karen Condouris, Daniela Plesa-Skwerer, Helen TagerFlusberg, Boston University School of Medicine Background: Findings on prosody competence in children with autism vary. Some show no differences between autistic children and typically developing controls TD ; in vocal affect naming Boucher, et al., 2000 ; . Others note that autistic children have a productive prosody deficit Shriberg, et al., 2001 ; and difficulty using stress Paul, et al., 2005 ; . Objective: To investigate the comprehension of affective prosody, and comprehension and production of linguistic prosody in autistic and TD children. Methods: We gave 19 autistic and 18 age and NVIQ matched TD children 7.5-18 years ; : Receptive and Production Lexical Ambiguity LAr & LAp ; and Filtered Speech FS ; . LAr involved auditory presentation of two syllable constructs with stress placed on the first T1 compound word ; , on second syllable T2 two-word phrase ; "HOTdog, " "hot DOG" ; in a match-to-picture task. LAp asked children to produce the appropriate stress pattern for the same constructs in the context of a sentence. The FS task used pre-recorded sentences happy, neutral, sad ; that were acoustically filtered to remove lexical content while maintaining affective prosody. Children were asked to label the speakers emotion for the filtered and then the unfiltered sentences. Results: We found no group differences in the LAr and FS tasks. The AUT group was significantly worse at linguistic stress production than the TD group U 98.5, p 0.026 ; . Conclusions: Children with autism successfully used linguistic and affective prosody to disambiguate words and to determine the emotional state of a speaker, while showing a clear deficit in linguistic prosody production. Funding: This research was funded by NIDCD U19 DC03610; H. Tager-Flusberg, PI ; and conducted as part of the NICHD NIDCD Collaborative Programs of Excellence in Autism, and by grant M01-RR00533 from the General Clinical Research Ctr. program of the National Center for Research Resources, National Institutes of Health. PS5.28 ATYPICAL LEXICAL PROCESSING IN HIGHFUNCTIONING AUTISM SPECTRUM DISORDER WITHOUT SPEECH DELAY Yoko Kamio, Diana Robins, Naoko Inada, Elizabeth Kelly, Brook Swainson, Deborah Fein, Kyushu University Background: Although individuals with high-functioning autism spectrum disorder HFASD ; have been reported to be different in how they process language, the dependence of lexical processing on perceptual components has not been clarified. Objectives: The present study examined automatic semantic and phonological processing in different ASD.
Topotecan response rate
Study group. Forty-seven patients were treated, including 22 with MDS RAEB, n 12; RAEB-T, n lo ; , and 25 with CMML. Patient characteristics are listed in Table 1. The median age was 66 years range, 39 to 84 ; and 81% were 2 6 0 years of age; 15 patients 32% ; were women. Chromosome 5 or 7 abnormalities were present pretreatment in 15 patients 32% ; , and trisomy 8 in four patients 9% ; . A normal karyotype was present in 14 patients 30% ; . Thrombocytopenia less than 50 x 103 pLwas found in 24 patients 51% ; . Mutations in the RAS gene were noted in five of 25 patients analyzed 20% ; . Response to therapy and outcome. Thirteen patients achieved a CR 28% ; and six had HI 13% ; . No patients died early within 2 weeks; nine died during induction 19% ; , six of them 13% ; with marrow hypoplasia and three 6% ; with persistent disease. Nineteen patients had primary resistant disease. Eight patients in whom CR occurred had pretreatment cytogenetic abnormalities that were searched for at the time of remission. These abnormalities involved chromosome 5 or 7 five patients, trisomy 8 in two patients, and llq23 in one patient. All eight patients showed disappearance of these abnormalities in CR. A CR was observed in six patients 27% ; with MDS, including three of 12 with RAEB 25% ; and three of 10 with RAEB-T 30% ; . In CMML, seven of 25 patients achieved CR 28% ; . The difference in response in the two groups was not significant P .96 ; . The median follow-up duration among patients who remain alive is 8 months. The median survival time was 10.5 months, and the median CR duration was 7.5 months. The actuarial survival and remission duration overall, and within MDS and CMML categories, is shown in Figs 1 and 2. The median number of courses given to patients on study was two range, one to 10 ; . Patients who achieved a response received a median number of three courses range, one to IO ; . The median maintenance dose of topotecan given to patients who achieved a response was l .25 mg m2 dfor 5 days; 35% of courses were given at 275% of the induction dose; 25% were at 65% and 40% were at 550%. Side effects. Myelosuppression excepted, side effects were mucositis 64% ; , which was severe grade 3 to 4 ; 19%, and diarrhea 32%; severe in 13% ; . Nausea and vomiting was reported in 23%, but was severe in only 2%. Other side effects occurred in less than 10% of patients Table 2 ; . Neurologic and cardiopulmonary complications were associated with other factors such as infections, fluid overload, and concomitant medications. Febrile episodes during neutropenia occurred in 40 pa and triac.
Residues. Arg364, in fact, has very low fluctuations in topo58 6.3 but not in topo70. Analyses presented below confirm these data, indicating that the linker domain and the N-terminal residues strongly perturb the dynamics of the Phe-361Lys-369 region that constitutes lip1, one of the two lips on the core of the enzyme that clamp around DNA. The fluctuations of core subdomain II are also strongly dampened Fig. 2 ; . The average fluctuations and standard deviation of this subdomain are 3.0 and 0.3 A, respectively, in topo70 , respectively, in topo58 6.3. compared with 3.6 and 0.8 A The decrease of the average fluctuations and standard deviation is nearly the same in core subdomain III average and standard deviation fluctuations of 3.5 and 0.3 A, in topo58 6.3 ; respectively, in topo70, versus 4.2 and 0.8 A Fig. 2 ; . In this protein region, some key residues maintain the same relative behavior in both simulations e.g., 519520 and 608609, which show high fluctuations, and Asp-533, which exhibits low fluctuations ; . Asp-533 is the only protein residue found crystallographically to contact directly the camptothecin derivative Topotecan Staker et al., 2002 ; . The C-terminal domain fluctuates less in topo70 than in topo58 6.3 average and standard deviation fluctuations of 3.3 and 0.2 A, respectively, in topo70, versus 3.9 and 0.6 A in topo58 6.3 ; and the relative maxima and minima fluctuations are almost completely maintained Fig. 2 ; . The DNA fluctuations do not show significant difference in the two simulations, with average fluctuations and standard deviation of 3.4 and 0.9, respectively, in topo58 6.3, versus 3.5 and 0.7 A in topo70. This agrees with the mean crystallographic B-factors of DNA atoms, which are 47.1 and 48.3 A2, respectively, for 1a31 and 1a36 crystallographic structures. S2 parameter for U W dihedral angles The flexibility of the protein backbone has also been examined through the calculation of an order parameter S2, which is related to the protein F C backbone dihedral angles Van der Spoel and Berendsen, 1997 ; . S2 gives a measure of the flexibility of the backbone, being 1 in a completely rigid system, or 0 in a system where all the possible conformations are sampled. The order parameter for topo70 and topo58 6.3, shown in Fig. 3, indicates that the backbone of both structures is quite rigid, with relatively few residues exhibiting S2 values , 0.7. In topo70, Glu-213 and Gly-214, two residues not present in the topo58 6.3 simulation, display a very high flexibility, with the S2 values for their respective C and F dihedral angles being 0.26 and 0.28. These residues are located at the C-terminal of the 12 N-terminal residues that were first detected through x-ray diffraction in the topo58 6.3-DNA complex where a cytosine rather than the favored thymine is present at the 1 position of the scissile strand PDB id 1ej9; Redinbo et al., 2000 ; . These residues have since been observed in other structures of topo70 in complex with DNA and toradol.
Topotecan drug insert
If the Executive has not named a Beneficiary, then such amounts shall be paid to the Executive's devisee, legatee, or other designee, or if there is no such designee, to the Executive's estate. Article 10 . Legal Fees and Notice 10.1 10.2 Payment of Legal Fees . To the extent permitted by law, the Company shall pay all legal fees, costs of litigation, prejudgment interest, and other expenses incurred by Executive in contesting a termination, if Executive prevails. Notice . Any notices, requests, demands, or other communications provided by this Agreement shall be sufficient if in writing and if sent by registered or certified mail to the Executive at the last address he has filed in writing with the Company or, in the case of the Company, at its principal offices to the attention of the General Counsel. Article 11 . Confidentiality and Noncompetition 11.1 Disclosure of Information . The Executive recognizes that he has access to and knowledge of confidential and proprietary information of the Company that is essential to the performance of his duties under this Agreement. a ; The Executive will not, during and for five 5 ; years after the term of his employment by the Company, in whole or in part, disclose such information to any person, firm, corporation, association, or other entity for any reason or purpose whatsoever, nor shall he make use of any such information for his own purposes, so long as such information has not otherwise been disclosed to the public or is not otherwise in the public domain except as required by law or pursuant to administrative or legal process and triazolam.
Piroxantone in the rhesus monkey. Investig. New Drugs, 11: 255261, 1993. Sung, C., Blaney, S., Cole, D., Balis, F., and Dedrick, R. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res., 54: 5118 5122, Balis, F., Blaney, S. M., McCully, C. L., Bacher, J. D., Murphy, R. F., and Poplack, D. G. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother. Pharmacol., 45: 259 264, Yeh, K. C., and Kwan, K. C. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J. Pharmacokinet. Biopharm., 6: 79 98, Rocci, M. L., Jr., and Jusko. W. J. LAGRAN program for area and moments in pharmacokinetics analysis. Comput. Programs Biomed., 16: 203216, 1983. Shipley, L., Brown, T., Cornpropst, J., Hamilton, M., Daniels, W., and Culp, H. Metabolism and disposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab. Dispos., 20: 849 855, Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Trassoff, P., Satterlee, W., Raber, M. N., and Plunkett, M. A Phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin. Oncol., 9: 491 498, Grunewald, R., Kantarjian, H., Du, M., Faucher, K., Tarassoff, P., and Plunkett, W. Gemcitabine in leukemia: a Phase I clinical, plasma, and cellular pharmacology study. J. Clin. Oncol., 10: 406 413.
Topotecan reimbursement
Topotecan treatment small cell lung cancer
Cupping espresso, laparoscopic appendectomy recovery time, hyperventilation during sleep, antiviral treatments and retrospective test. Clone 5 pinot, perfusion jobs in canada, hair loss black women and magic bullet records or delirium watch.
Topotecan msds
Ropotecan, toppotecan, topotecsn, topoteecan, topoteczn, 6opotecan, topotecah, topoteccan, topotecxn, topoteacn, topotscan, topot3can, t9potecan, tipotecan, topltecan, tlpotecan, 5opotecan, topoecan, ttopotecan, topoteca.
Discount Drugs
Topotecan liposome, topotecan chemotherapy drugs, topotecan hycamtin treatment, topotecan and cervical cancer and topotecan ewing. Topotecan response rate, topotecan drug insert, topotecan reimbursement and topotecan treatment small cell lung cancer or topotecan msds.
|
